Experimental cell therapy aims to unlock transplants for Hard-to-Match patients
NCT ID NCT06056102
Summary
This early-stage study is testing a new cell therapy for people who have been waiting over a year for a kidney transplant and have immune systems that would reject almost any donor kidney. Researchers will collect a patient's own immune cells, modify them in a lab to target antibody-producing cells, and infuse them back after chemotherapy. The main goals are to see if this approach is safe and if it can lower the antibody levels that block transplant matching.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY FAILURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital: Transplantation (Site #: 71107)
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NYU Langone Health (Site #: 71177)
RECRUITINGNew York, New York, 10016, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Pennsylvania Medical Center (Site #: 71111)
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.